JP2019521105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521105A5 JP2019521105A5 JP2018563888A JP2018563888A JP2019521105A5 JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5 JP 2018563888 A JP2018563888 A JP 2018563888A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- antibody
- polymorphism
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 229960002224 eculizumab Drugs 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108010028773 Complement C5 Proteins 0.000 claims description 8
- 230000024203 complement activation Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 2
- 206010065553 Bone marrow failure Diseases 0.000 claims description 2
- 102100031506 Complement C5 Human genes 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 102200094439 rs373359894 Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003814 drug Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102200094440 rs56040400 Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346683P | 2016-06-07 | 2016-06-07 | |
| US62/346,683 | 2016-06-07 | ||
| PCT/IB2017/053245 WO2017212375A1 (en) | 2016-06-07 | 2017-06-01 | Anti-c5 antibody for treating patients with complement c5 polymorphism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521105A JP2019521105A (ja) | 2019-07-25 |
| JP2019521105A5 true JP2019521105A5 (enExample) | 2020-07-09 |
Family
ID=59078125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563888A Pending JP2019521105A (ja) | 2016-06-07 | 2017-06-01 | 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190225678A1 (enExample) |
| EP (1) | EP3464351A1 (enExample) |
| JP (1) | JP2019521105A (enExample) |
| CN (1) | CN109328197A (enExample) |
| WO (1) | WO2017212375A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3468990T (lt) | 2016-06-14 | 2024-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antikūnai ir jų panaudojimas |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| PH12022550167A1 (en) | 2019-08-16 | 2023-05-08 | Regeneron Pharma | High concentration anti-c5 formulations |
| MX2022004712A (es) * | 2019-10-25 | 2022-08-04 | Regeneron Pharma | Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| CN119409815B (zh) * | 2025-01-07 | 2025-04-08 | 天辰生物医药(苏州)有限公司 | 抗人补体c5 vhh抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| AU2008228247A1 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| BRPI0916668B1 (pt) | 2008-08-05 | 2021-12-28 | Novartis Ag | Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor |
| CN109045296A (zh) * | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| NZ629829A (en) * | 2010-04-30 | 2015-11-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
| TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| CN105143261B (zh) * | 2013-01-31 | 2021-04-09 | 首尔大学校产学协力团 | C5抗体以及用于预防和治疗补体-相关的疾病的方法 |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2018511557A (ja) * | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | ２種以上の抗ｃ５抗体の組み合わせおよび使用方法 |
-
2017
- 2017-06-01 CN CN201780034701.9A patent/CN109328197A/zh active Pending
- 2017-06-01 JP JP2018563888A patent/JP2019521105A/ja active Pending
- 2017-06-01 US US16/306,654 patent/US20190225678A1/en not_active Abandoned
- 2017-06-01 WO PCT/IB2017/053245 patent/WO2017212375A1/en not_active Ceased
- 2017-06-01 EP EP17731296.4A patent/EP3464351A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521105A5 (enExample) | ||
| Laske | Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease | |
| Dimachkie et al. | Chronic inflammatory demyelinating polyneuropathy | |
| Wieszczycka et al. | Lanthanides and tissue engineering strategies for bone regeneration | |
| JP2013166765A5 (enExample) | ||
| JP2017518316A5 (enExample) | ||
| BR112019007453A2 (pt) | organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina | |
| JP2019528285A5 (enExample) | ||
| Du et al. | The ageing immune system as a potential target of senolytics | |
| Fatima et al. | Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment | |
| Byvaltsev et al. | Comparative analysis of the effectiveness of PRP therapy and facetoplasty in older patients with isolated lumbar facet syndrome: long-term results of a randomized controlled trial | |
| Faraj et al. | The misconceptions about epilepsy disease within health sector workers in the City of tabuk, Saudi Arabia | |
| DK3137093T3 (en) | TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD) | |
| EP3632447A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES | |
| DE59909356D1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| TW202300518A (zh) | 抗N3pGlu類澱粉β抗體及其用途 | |
| Stevelink et al. | Epilepsy surgery in patients with genetic refractory epilepsy: A systematic review | |
| CN116981690A (zh) | 抗-淀粉样蛋白β抗体及其用途 | |
| Nobile-Orazio et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders | |
| Natalia et al. | COSTS FOR REVERSE HEMOSTATIC THERAPY OF INTERNAL CEREBRAL BLEEDING WITH THE USE OF PROTHROMBIN COMPLEX CONCENTRATE | |
| Prins | Immunotherapy against amyloid-β in Alzheimer’s disease: an overview | |
| Ahmad et al. | AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions. | |
| Olupot-Olupot et al. | Effects of hydroxyurea treatment on malaria infections in Sub-Saharan Africa | |
| NITZJATI et al. | ANALYTICAL REVIEW OF LITERATURE. PREVALENCE OF ACUTE INFECTIOUS AND INFLAMMATORY DISEASES OF JAW IN CHILDREN AND GENERAL PRINCIPLES OF COMPLEX TREATMENT | |
| MA | Clinical Practice Guideline |